Kane Biotech (TSE:KNE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech has seen a substantial revenue increase in the third quarter of 2024, primarily driven by the first commercial sale of its revyve™ Antimicrobial Wound Gel. The company also announced significant corporate developments, including new distribution agreements and regulatory approvals, positioning it well for future growth in the wound care market.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.